Key result
The management of acute coronary syndrome in cancer patients requires an individualized approach considering cancer type, prognosis, and bleeding risk, as there is a lack of randomized clinical trial data for this population.
Why the study?
Treatment of myocardial infarction in cancer patients is challenging because clinical trial data including cancer patients with ACS are very limited.
Management of acute coronary syndrome in cancer patients requires a highly individualized, multidisciplinary approach that carefully weighs the competing risks of bleeding and thrombosis.
Answers are grounded in this paper and cite their sources.
Supports individualized ACS management in cancer now; leaves open RCT-guided protocols by subtype and prognosis.
Acute coronary syndrome (ACS) and oncological disease are more frequently observed in the general population as discussed in the part I of this article. Treatment of myocardial infarction in oncological patients becomes a real struggle for clinicians, especially that the data from clinical trials including cancer patients with ACS are very limited. The choice of treatment modality should consider many existing factors considering the type of ACS – non-ST-segment elevation myocardial infarction vs ST-segment elevation myocardial infarction, patient’s condition, type of cancer and oncological treatment applied. Taking into consideration above mentioned factors, clinicians have to face three therapeutic options: invasive, conservative or combination of both in order to choose the best and most beneficial treatment. This article summarizes the current therapeutic approach to the management of ACS in cancer patients.
No takes yet. Share an insight, caveat, or question.
Grzegorz Piotrowski (2020) conducted a review in Acute coronary syndrome in cancer patients. Invasive and conservative treatment options was evaluated. The management of acute coronary syndrome in cancer patients requires an individualized approach considering cancer type, prognosis, and bleeding risk, as there is a lack of randomized clinical trial data for this population.
Synapse has enriched 10 related papers. Consider them for comparative context: